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the conclusions are not verified by experience. Ex-
perimental science is the queen of sciences and
the goal of all speculation.’’
Roger Bacon (1214e1294), philosopher and advo-
cate of modern scientific method.
Jay Kaufman has attempted to provide a scholarly
assessment of pitfalls in attempting to assign the cause
of disease outcomes to apparent racial differences
(Kaufman, 2008). Apart from a number of factual errors
in his arguments, he has continued to follow the same
path as other authors, whom he appears to deride, in
misinterpreting the conclusions of our 2001 paper,
‘‘Lesser response to angiotensin-converting-enzyme in-
hibitor therapy in black as compared with white patients
with left ventricular dysfunction’’ published in the New
England Journal of Medicine (Exner, Dries, Domanski,
Cohn, 2001).
Despite Kaufman’s assertions, the matched-cohort
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data was not an attempt to replicate a randomized con-
trolled trial but to improve, albeit with remaining in-
equalities, our ability to identify potential reasons for
previously reported differences in outcome (Dries
et al., 1999). Our analysis was never suggested to be
more than hypothesis generating. The over-interpreta-
tion by Kaufman and others served their purposes,
not ours. In addition, his criticisms of our analytic ap-
proach are mostly inaccurate.
Our statements in the New England Journal of Med-
icine article were intentionally worded to discourage
mis-interpretation or over-interpretation of our findings.
Since prior heart failure trials were conducted predom-
inantly in white subjects and possible differences of re-
sponse in blacks were uncovered it was correct to state
that ‘‘the overall population of black patients with heart
failure may be underserved by current therapeutic rec-
ommendations’’ and ‘‘it seems appropriate to consider
current therapeutic recommendations as applying to
white patients but not necessarily to black patients’’.
These comments are clearly in the context of a hypothe-
sis, not a definitive conclusion. Our recommendation for
‘‘clinical trials in black patients that are designed pro-
spectively to evaluate therapeutic responses.’’ (Exner
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for the need of additional, prospective randomized data.
We recognize that our matched-cohort design, as
with any study of this kind, was imperfect. Yet, many
of Kaufman’s criticisms are unmerited. Our matching
strategy was described as ‘‘questionable because race
was not randomized’’ (Kaufman, 2008). The matching
method used was both appropriate and scientifically
valid. The comment that ‘‘once the data are already col-
lected, however, one can’t generally do better by throw-
ing away a large proportion of these data’’ (Kaufman,
2008) is erroneous. In fact, a paper used to support
Kaufman’s criticisms states that ‘‘matching can be ex-
pected to increase efficiency’’ when both the matching
variables, and exposure, self-identified race, are nega-
tively associated with outcome (Greenland & Morgen-
stern, 1990). That was the situation for our analysis.
Despite Kaufman’s assertions related to our statistical
models, we were cognizant of issues related to residual
confounding and misclassification and used great care
to deal with these issues as best we could. We acknowl-
edged these limitations in our paper by stating that ‘‘no
degree of statistical adjustment can ensure complete
comparability’’ (Exner et al., 2001, p. 1357). Further,
the comment that ‘‘it is well appreciated in the theoret-
ical epidemiologic literature that groups with higher
baseline risk will in general have more modest response
to treatment. (Maldonado & Greenland, 2002)’’
(Kaufman, 2008, emphasis added) is inaccurate. This
theoretical concept is not universally accepted (Dawid,
2002). Moreover, it is well known that patients with left
ventricular systolic dysfunction and a higher baseline
risk derive greater benefit from therapeutic interven-
tions, in terms of absolute benefit, than do patients
with a lower baseline risk (Moss, 2000; Sheldon
et al., 2000).
It is clear that a therapeutic reduction of hospitaliza-
tion rate is a particularly sensitive guide to efficacy in
sicker patients, as evidenced by its usefulness in recent
studies in advanced Classes III and IV heart failure
(Packer et al., 2001, 2002). Indeed, Kaufman uses mor-
tality as a guide to severity of heart failure, even though
differences in mortality, comparing white and black pa-
tients, may be a result of health management disparities.
Furthermore, Kaufman claims that in our paper ‘‘the
null finding for mortality is largely ignored.’’ (Kauf-
man, 2008). In doing so he fails to appreciate that in
the SOLVD Prevention Trial, which was the source of
most of our black patients, mortality was not reduced
by enalapril in the overall population (SOLVD Investi-
gators, 1992). We also clearly reported that differences
in rates of hospitalization for heart failure wereresponsible for the differences in outcome that were ob-
served between the two groups. The abstract to our pa-
per specified ‘‘no significant change in the risk of death
was observed in association with enalapril therapy in ei-
ther group’’ (Exner et al., 2001, p. 1351). These data
were further highlighted in Table 3 of our paper and
specific comments were made that ‘‘mortality was sim-
ilar among the black patients and the matched white pa-
tients regardless of treatment assignment’’ and that ‘‘no
significant alteration in mortality was observed in asso-
ciation with enalapril therapy’’ (Exner et al., 2001).
Thus, it is neither surprising nor unexpected that subse-
quent analyses (Dries, Strong, Cooper, & Drazner,
2002; Shekelle et al., 2003) have confirmed our
findings.
The analysis we reported in 2001 never attempted to
identify genetic or environmental factors that might
contribute to our observations. Studies demonstrating
lesser antihypertensive potency of ACE inhibitors in
black than in white hypertensive patients (Cohn et al.,
2004) also have made no such attempt. On two points
we agree with Kaufman. The findings from our paper
have been both over-interpreted and mis-interpreted
by others. Our analysis was conducted to investigate
whether observed differences in outcome could, in
part, be explained by differences in therapeutic re-
sponse. If confirmed, we planned to conduct additional,
definitive research in this area aimed at improving the
lives of patients with heart failure. This research has
been completed. We also agree that a ‘‘randomized
controlled trial (RCT) is widely considered to be
the gold standard for establishment of causality in
biomedicine’’ (Kaufman, 2008). Our analysis has
been followed by at least one prospective randomized
trial designed to address therapeutic response in
a self-identified black population with heart failure
(Taylor et al., 2004), and that trial has identified a ther-
apy that reduces mortality, reduces hospitalization, and
enhances quality of life in these patients. Such data are
critical both in providing valid evidence and in assisting
physicians in treating individual patients.References
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